Collectively, our findings indicate that API treatment ameliorated HuR depletion and bone loss in OVX mice, supporting that API exerts a positive impact on bone formation and holds potential as a therapeutic agent for osteoporosis. This evidence concerns the gene ELAVL1 and osteoporosis.